Publicacións en colaboración con investigadores/as de Hospital Juan Ramón Jiménez (13)

2024

  1. Heteroatom-tagged proteomics of lung cancer and chronic obstructive pulmonary disease human serum reveal alterations in selenoproteins

    Microchemical Journal, Vol. 199

2023

  1. American Heart Association's life simple 7 and the risk of atrial fibrillation in the PREDIMED study cohort

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 33, Núm. 6, pp. 1144-1148

  2. Metallomic Signatures of Lung Cancer and Chronic Obstructive Pulmonary Disease

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  3. Untargeted Metabolomic Study of Lung Cancer Patients after Surgery with Curative Intent

    Journal of Proteome Research, Vol. 22, Núm. 11, pp. 3499-3507

2021

  1. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics

    EBioMedicine, Vol. 73

2019

  1. Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain

    Clinical and Translational Oncology, Vol. 21, Núm. 8, pp. 1076-1084

2017

  1. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

2015

  1. Prediction of serious complications in patients with seemingly stable febrile neutropenia: Validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study

    Journal of Clinical Oncology, Vol. 33, Núm. 5, pp. 465-471

2011

  1. Invasive fungal infections in onco-haematology: A spanish perspective

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152